Fig. 2.
Monitoring of EBV-DNA load in patient 2.
A 39-year-old woman with AML received a TCD bone marrow graft from a mismatched unrelated donor. Grade I GVHD developed after engraftment. Four CTL infusions were given starting from day +67. A booster of TCD marrow was given on day +134 because of threatening rejection. Cyclosporin A was continued during follow-up. *EBV-DNA was not detected in the DNA equivalent of 105 cells.
